Ginsenoside composition and application thereof

Abstract

The invention discloses a ginsenoside composition and an application thereof, and particularly relates to an application of the ginsenoside composition in preparation of a medicine for treating asthma. The core of the composition is that the composition comprises the following components in specific parts by weight: 4-8 parts of ginsenoside Rg1 and 1-3 parts of ginsenoside Rb1, and 2-4 parts of total ginsenoside which takes effect together with one of the ginsenoside Rg1 and the ginsenoside Rb1 and is prepared through standardization, and the total content of the Rg1 and the Rb1 in the total ginsenoside is 50-70%. According to the present invention, the known pure saponin product and the standardized total saponin rich in the specific unknown saponin group are combined according to the specific ratio so as to produce the unexpected synergistic effect; pharmacodynamic experiments prove that the composition can significantly improve asthma symptoms and effectively inhibit airway inflammation, mucus hypersecretion and immune imbalance, and the curative effect of the composition is significantly superior to that of a single component or common total saponins. Meanwhile, the product quality is stable and controllable through a specific extraction and purification process.

Description

Technical Field

[0001] This invention relates to the pharmaceutical field, and in particular to a ginsenoside extract and its uses. Background Technology

[0002] Asthma is a common chronic inflammatory airway disease characterized by airway hyperresponsiveness, reversible airflow limitation, and a complex inflammatory process involving multiple immune cells, such as eosinophils and T lymphocytes. Clinically, it often manifests as recurrent episodes of wheezing, shortness of breath, chest tightness, and cough. Currently, inhaled corticosteroids (ICS) and β2-receptor agonists are the mainstream treatments; however, long-term use of corticosteroids can lead to systemic side effects such as osteoporosis and hyperglycemia. Therefore, developing safer alternative or adjuvant therapies is urgently needed.

[0003] Ginseng, a traditional and precious Chinese medicinal herb, is recorded in the Pharmacopoeia of the People's Republic of China as having the effects of "greatly replenishing vital energy, tonifying the spleen and benefiting the lungs." Modern pharmacological research has confirmed that the main active ingredient of ginseng—total ginsenosides—has significant immunomodulatory and anti-inflammatory effects. Current research on ginsenosides mainly focuses on two directions: one is to conduct in-depth molecular mechanism exploration of single saponin monomers (such as Rg1, Rb1, Rh2, Re, etc.); the other is to observe the overall pharmacological efficacy of crude extracts of total ginsenosides, which have complex and variable compositions.

[0004] However, both of these research approaches have significant drawbacks: (1) Limitations of single components: Single saponin monomers have relatively single targets and are difficult to fully regulate the complex immune inflammatory network involved in asthma (such as Th1 / Th2 imbalance, Treg / Th17 ratio imbalance, etc.). Their efficacy is limited and it is difficult to simulate the synergistic effect of ginseng as a whole with "multi-component and multi-target".

[0005] (2) The extensive nature of total saponin research: Existing research on ginseng total saponins mostly stays at the level of "mixtures being effective". The sources of raw materials and extraction and purification processes vary greatly, resulting in huge fluctuations in the composition and content of various saponins in the final product, and the efficacy cannot be stably replicated. More importantly, the existing technology only regards total saponins as a drug with unknown components, and has not revealed that by precisely controlling the absolute content, relative ratio and overall purity of key known saponins (Rg1, Rb1) and utilizing their synergistic effect with specific unknown saponin component groups in total saponins, it is possible to achieve precise and efficient treatment of asthma.

[0006] There is a clear technological gap in the existing technology: it has not been disclosed or suggested that combining specific weight proportions (4-8:1-3) of Rg1 and Rb1 with total ginsenosides prepared through a specific standardized process, with the Rg1+Rb1 content controlled within the range of 50%-70%, can produce an unexpected synergistic effect, thereby significantly improving the therapeutic effect on asthma (especially allergic asthma). The purpose of this invention is precisely to fill this technological gap. Summary of the Invention

[0007] To address the shortcomings and deficiencies of existing technologies, this invention aims to provide a novel use of a ginsenoside composition with a specific composition in the preparation of medications for treating asthma (especially allergic asthma). Another objective of this invention is to provide a ginsenoside composition itself that exhibits controllable quality, stable efficacy, and synergistic effects. This composition is designed based on a novel concept: precisely combining known pure ginsenosides with standardized total ginsenosides to produce a synergistic therapeutic effect.

[0008] The specific technical solution of this invention is as follows: The use of a ginsenoside composition in the preparation of a drug for treating asthma, wherein the ginsenoside composition comprises 4 to 8 parts by weight of ginsenoside Rg1 and 1 to 3 parts by weight of ginsenoside Rb1.

[0009] As a further optimization of the application of the present invention, the ginsenoside composition further includes 2 to 4 parts by weight of total ginsenosides.

[0010] Furthermore, the total weight of ginsenoside Rg1 and ginsenoside Rb1 in the ginsenoside composition accounts for 80% to 90% of the total weight of the composition. Rg1 and Rb1 in the ginsenoside composition include directly added pure Rg1 and pure Rb1, as well as a portion of Rg1 and Rb1 derived from total ginsenosides.

[0011] Furthermore, the total weight of ginsenoside Rg1 and ginsenoside Rb1 in the total ginsenosides accounts for 50% to 70% of the total weight of the total ginsenosides; more preferably 62%.

[0012] A key aspect of this invention is that the composition of the ginsenosides, excluding ginsenosides Rg1 and Rb1, in the total ginsenosides is determined and fixed through the raw materials and processes used in the preparation of the total ginsenosides. Specifically, the total ginsenosides are prepared by the following steps: a) Extraction: Using the dried main root of ginseng (Araliaceae family) as raw material, extract with 6-10 times the amount of 50%-70% ethanol aqueous solution by heating and reflux 2-3 times, each time for 1-2 hours, and combine the extracts; b) Purification: The obtained extract was concentrated until there was no alcohol odor, and then dispersed in water to prepare a loading solution, which was then passed through a D101 macroporous adsorption resin column. c) Elution: First, elute with 3-5 column volumes of deionized water to remove impurities, then elute with 4-6 column volumes of 60%-70% ethanol aqueous solution, and collect the ethanol eluent. d) Post-processing: The ethanol eluent was concentrated to dryness under reduced pressure and then vacuum dried at 60°C to obtain the total ginsenosides.

[0013] A preferred method for preparing a ginsenoside composition is as follows: 4-8 parts by weight of ginsenoside Rg1, 1-3 parts by weight of ginsenoside Rb1, and 2-4 parts by weight of total ginsenoside powder prepared according to the above method are physically mixed and mixed in a V-type mixer at a speed of 20-30 rpm for 30-60 minutes until the mixture is homogeneous.

[0014] Furthermore, the preparation method of the drug is as follows: the ginsenoside composition is mixed with pharmaceutically acceptable excipients to prepare commonly used dosage forms such as tablets, capsules, granules or oral liquids.

[0015] Furthermore, the asthma described is allergic asthma.

[0016] A second aspect of the present invention provides a ginsenoside composition comprising 4-8 parts by weight of ginsenoside Rg1, 1-3 parts by weight of ginsenoside Rb1, and 2-4 parts by weight of total ginsenosides; wherein the total weight of ginsenoside Rg1 and ginsenoside Rb1 in the total ginsenosides accounts for 50%-70% of the total weight of the total ginsenosides, and preferably is prepared by the method for preparing total ginsenosides described in the first aspect of the present invention.

[0017] The present invention also discloses a pharmaceutical preparation comprising the above-described ginsenoside composition and pharmaceutically acceptable excipients.

[0018] Based on the above-described inventive principles, the beneficial effects of this invention are as follows: This invention scientifically combines specific weight proportions of pure ginsenosides Rg1 and Rb1 with a total ginsenoside prepared through a standardized process, resulting in an unexpected synergistic effect. Pharmacodynamic experiments have confirmed that the final composition of this invention exhibits significant efficacy in all core evaluation indicators, including improving asthma behavioral scores, inhibiting pulmonary inflammatory cell infiltration, reducing airway mucus secretion and collagen deposition, lowering systemic and local inflammatory factor (IL-4, IL-5, IL-33) levels, and inhibiting the activation of the MAPK / NF-κB key signaling pathway. This efficacy is superior to existing asthma treatments. This effect cannot be simply predicted or inferred by those skilled in the art based on the activity of a single component or ordinary total saponins.

[0019] This invention constructs a precise quality control system through specific raw materials, specific extraction and purification processes (such as D101 resin and 65% ethanol elution) as defined in the claims, and specific total content (80%-90%) and proportion of Rg1 and Rb1 in the final composition. This preparation system not only ensures the stability of the core known components, but more importantly, it fixes the compositional profile of unknown saponins in total ginseng saponins, thereby guaranteeing the consistency of the material basis for the synergistic effect. This fundamentally solves the industry problem of batch-to-batch efficacy fluctuations in traditional Chinese medicine compound preparations, ensuring the stable, reliable, and reproducible efficacy of the product of this invention.

[0020] This invention also proposes and verifies a novel composition that uses standardized total saponins as a carrier, specific known saponins as a regulatory means, and fully utilizes the synergistic contribution of unknown saponins. This composition not only brings excellent therapeutic effects to this invention, but also provides a new technical path for developing other natural product-based drugs for the treatment of complex diseases. Attached Figure Description

[0021] Figure 1 These are pathological sections of lung tissue from mice in the Control group, Model group, GS-L group, and Composition B group as described in Example 4 of this invention.

[0022] Figure 2 is a quantitative statistical chart of key pharmacodynamic indicators in each group of mice in Example 4 of the present invention. Figure 2A ( ) is a statistical bar chart showing the eosinophil count in the bronchoalveolar lavage fluid of mice in each group; Figure 2B The image shows a bar chart illustrating the statistical levels of IL-4 in the serum of mice in each group. Figure 2C The image shows a bar chart illustrating the statistical levels of IL-5 in the serum of mice in each group. Figure 2D (The following is a bar chart showing the relative expression levels of MAPK1 mRNA in the lung tissues of mice in each group.) Figure 2E The bar chart shows the relative expression levels of NF-κB p65 mRNA in the lung tissues of mice in each group. Detailed Implementation

[0023] The present invention will be further described below with reference to several specific embodiments and accompanying drawings, but the scope of protection of the present invention is not limited thereto. Unless otherwise specified, the experimental methods used in the present invention are all conventional methods, and the materials and reagents used are all commercially available.

[0024] The dried taproot of ginseng (Araliaceae family) was pulverized. 1 kg of ginseng powder was weighed and extracted twice by reflux with 8 times its volume of 60% ethanol aqueous solution, 1.5 hours each time. The extracts were combined. The extract was concentrated under reduced pressure at 60°C until no alcohol odor remained, and then dispersed in water to 2 L to prepare a loading solution. The loading solution was passed through a pre-treated D101 macroporous adsorption resin column (1 L column volume) at a flow rate of 2 BV / h. First, it was eluted with 4 column volumes of deionized water at a flow rate of 4 BV / h, and the water wash was discarded. Then, it was eluted with 5 column volumes of 65% ethanol aqueous solution at a flow rate of 2 BV / h, and this ethanol eluent was collected. The ethanol eluent was concentrated under reduced pressure at 60°C to obtain an extract, which was then dried in a vacuum drying oven at 60°C to constant weight to obtain standardized total ginsenosides (denoted as GS-H).

[0025] HPLC analysis showed that the total content of ginsenosides Rg1 and Rb1 in this product was 62% (by weight), which meets the requirements of claims 4 and 6 of this invention.

[0026] The preparation method is the same as that in Example 1a, except that the ethanol concentration is changed and 50% ethanol is used for elution to obtain ginsenosides with a total content of 58% Rg1+Rb1.

[0027] The preparation method is the same as that in Example 1a, except that the ethanol concentration is changed and 70% ethanol is used for elution to obtain ginsenosides with a total content of 65% Rg1+Rb1.

[0028] Common ginsenosides were prepared using conventional methods. 1 kg of ginseng powder from the same source was extracted three times by reflux with 10 times the volume of water, each time for 1 hour. The extracts were combined. After concentration, the extract was passed through a D101 macroporous resin and eluted with 30% ethanol. The eluent was collected, concentrated, and dried to obtain common ginsenosides (denoted as GS-L).

[0029] HPLC analysis showed that the total content of ginsenosides Rg1 and Rb1 in this product was 35% (by weight), which is lower than the 50% lower limit required by this invention.

[0030] Composition A (pure): Accurately weigh 6 parts by weight of pure ginsenoside Rg1 and 2 parts by weight of pure ginsenoside Rb1, and mix them thoroughly. This composition does not contain total ginsenosides.

[0031] Composition B (Example 1a): 6 parts by weight of pure Rg1, 2 parts by weight of pure Rb1, and 3 parts by weight of GS-H powder prepared in Example 1a were accurately weighed and mixed evenly in a V-type mixer. The total content of Rg1 and Rb1 in the final composition was calculated to be 89.6% (by weight).

[0032] Composition C (Example 2): GS-L prepared in Example 2 was used as the sole active ingredient, with a total content of 35% for Rg1+Rb1.

[0033] Composition D: Accurately weigh 4 parts by weight of pure ginsenoside Rg1 and 1 part by weight of pure ginsenoside Rb1, and mix them thoroughly. This composition does not contain total ginsenosides.

[0034] Composition E: Accurately weigh 8 parts by weight of pure ginsenoside Rg1 and 3 parts by weight of pure ginsenoside Rb1, and mix them thoroughly. This composition does not contain total ginsenosides.

[0035] Composition F: Accurately weigh 5 parts by weight of pure Rg1, 1.5 parts by weight of pure Rb1, and 3.5 parts by weight of GS-H powder prepared in Example 1a, and mix them thoroughly. The total content of Rg1 and Rb1 in this composition is calculated to be 86.7% (by weight).

[0036] Composition G: Accurately weigh 7 parts by weight of pure Rg1, 2.5 parts by weight of pure Rb1, and 4 parts by weight of standardized ginsenoside powder prepared in Example 1a, and mix them evenly. The total content of Rg1 and Rb1 in this composition is calculated to be 88.7% (by weight).

[0037] Composition H: Accurately weigh 4 parts by weight of pure Rg1, 1.5 parts by weight of pure Rb1, and 4.5 parts by weight of standardized ginsenoside powder prepared in Example 1a, and mix thoroughly. The total content of Rg1 and Rb1 in this composition is calculated to be 82.9% (by weight).

[0038] Composition I: Accurately weigh 6 parts by weight of pure Rg1, 2 parts by weight of pure Rb1, and 3 parts by weight of standardized ginsenoside powder prepared in Example 1b, and mix them evenly. The total content of Rg1 and Rb1 in this composition is calculated to be 88.5% (by weight).

[0039] Composition J: Accurately weigh 6 parts by weight of pure Rg1, 2 parts by weight of pure Rb1, and 3.5 parts by weight of standardized ginsenoside powder prepared in Example 1c, and mix thoroughly. The total content of Rg1 and Rb1 in this composition is calculated to be 89.3% (by weight).

[0040] 1. Laboratory animals and grouping Sixty female Balb / c mice were randomly divided into 6 groups (n=10): Group 1: Blank control group (Control group) Group 2: Asthma Model Group Group 3: Composition A (pure product): A pure product mixture consisting of 6 mg / kg Rg1 and 2 mg / kg Rb1 was administered by gavage.

[0041] Group 4: Common ginsenosides group (GS-L): 120 mg / kg of GS-L was administered by gavage.

[0042] Group 5: Standardized Ginsenosides Group (GS-H): 120 mg / kg of GS-H was administered by gavage.

[0043] Group 6: Composition Group B: The composition of the present invention was administered by gavage at a total dose of 120 mg / kg, containing 6 mg / kg Rg1, 2 mg / kg Rb1 and about 36 mg / kg GS-H.

[0044] 2. Modeling and drug administration

[0045] This experiment used the classic ovalbumin (OVA) sensitization and challenge method to establish a mouse model of allergic asthma.

[0046] On days 0, 7, and 14 of the experiment, mice in the asthma model group, composition A (pure product), ordinary ginseng total saponins group (GS-L), standardized ginseng total saponins group (GS-H), and the composition group of the present invention were sensitized by intraperitoneal injection.

[0047] Each mouse was injected with 0.2 mL of sensitization solution containing 10 μg OVA (dissolved in physiological saline) and 1 mg aluminum hydroxide adjuvant.

[0048] The blank control group mice were injected intraperitoneally with the same volume of physiological saline at the same time point.

[0049] Starting from day 21 of the experiment, the patient underwent 7 consecutive days of nebulized stimulation and drug treatment.

[0050] Administration: One hour before the daily nebulization challenge, mice in each treatment group were administered the drug by gavage. Groups A, GS-L, GS-H, and B were given the corresponding test drugs (dosages as shown in Example 4), all prepared with physiological saline. The Control and Model groups were administered an equal volume of physiological saline by gavage.

[0051] Nebulization challenge: On days 26, 27, and 28 (the last three days) of drug administration, all mice except the Control group were placed in a closed nebulizer and challenged with 2.5% OVA saline solution using an air compressor nebulizer for 30 minutes each time. Mice in the Control group were nebulized with saline solution.

[0052] Twenty-four hours after the last nebulization challenge, samples were collected and tested from the mice. During each nebulization challenge, the behavior of each mouse was observed and recorded by researchers who were unaware of the group assignments.

[0053] Inflammatory cell count: The cell pellet after BALF centrifugation was resuspended in PBS, and the total number of cells and the classification count of eosinophils, neutrophils, lymphocytes, etc. were performed using an automated blood cell analyzer or an artificial blood cell counting chamber.

[0054] During nebulization provocation, the Model group mice exhibited severe asthma symptoms (score 2.7±0.5), while all treatment groups showed varying degrees of improvement. Among them, group B of the present invention showed the mildest symptoms and the lowest score (0.9±0.2), and its eosinophil count, a crucial finding in BALF, was also reduced to the lowest level (2.1±0.5 ×10⁻⁶). 5 ( / mL), significantly better than other treatment groups. Detailed data are shown in Table 1.

[0055] Methods: The left lung tissue fixed with paraformaldehyde was dehydrated, embedded in paraffin, and then cut into 4-5 μm thick sections.

[0056] HE staining: to observe the inflammatory cell infiltration around the airway and blood vessels, the thickness of the airway wall, and the integrity of the epithelial cells.

[0057] PAS staining: Observe the proliferation of goblet cells and mucus secretion in the airway, and calculate the proportion of PAS-positive staining area in the airway using image analysis software.

[0058] Masson staining: Observe the collagen fiber deposits around the airways and blood vessels (shown in blue) to assess the degree of airway remodeling.

[0059] See attached document for lung tissue pathology section results. Figure 1 .

[0060] HE staining: In the Control group, the tracheal epithelial system was relatively intact, with no obvious pathological changes. In the Model group, extensive inflammatory cell infiltration and thickening of the airway walls were observed around the airways. The GS-L group showed moderate improvement. The combined group B showed significant improvement, with the lung structure closest to normal and inflammatory infiltration greatly suppressed.

[0061] PAS staining: Increased mucus secretion in the airways of the Model group. In the Group B composition, mucus blockage in the airway lumen was essentially eliminated, and goblet cell proliferation was optimally inhibited.

[0062] Masson staining: The Model group showed significant blue collagen fiber deposition. Composition B had the smallest collagen deposition area, indicating its strongest inhibitory effect on airway remodeling.

[0063] Anesthetize mice with an appropriate amount of anesthetic (such as sodium pentobarbital).

[0064] Blood collection: Approximately 1.0 mL of blood is collected by enucleation and placed in an anticoagulant tube for complete blood cell analysis and serum separation (for ELISA detection).

[0065] Bronchoalveolar lavage fluid (BALF) collection: Mice were euthanized, their tracheas were exposed, and endotracheal intubation was performed. The lungs were slowly lavaged twice with 1 mL of pre-cooled PBS solution, and the lavage fluid was recovered (recovery rate >80%). The recovered BALF was centrifuged at 1500 rpm for 10 minutes at 4°C, and the supernatant was stored at -80°C for later use in the detection of inflammatory factors; the cell pellet was used for inflammatory cell counting.

[0066] Lung tissue collection: Mouse lungs were completely removed and rinsed with pre-cooled PBS. The left lung lobe was fixed in 4% paraformaldehyde for subsequent pathological section preparation. The right lung lobe was aliquoted and rapidly frozen in liquid nitrogen, then transferred to a -80°C cryogenic freezer for RNA extraction.

[0067] Take mouse serum or BALF supernatant and strictly follow the instructions for the IL-4, IL-5 and IL-33 ELISA kits.

[0068] The absorbance (OD value) of each well was measured at a wavelength of 450 nm using an ELISA reader, and the concentration of inflammatory factors in each sample was calculated based on the standard curve.

[0069] RT-qPCR detection of pathway-related protein mRNA expression: Total RNA extraction: Take about 50 mg of frozen lung tissue, add 1 mL of TransZol Up lysis buffer, homogenize, and extract total RNA according to the kit instructions. Then, test the RNA purity and concentration.

[0070] cDNA synthesis: 1 μg of total RNA was reverse transcribed into cDNA using a reverse transcription kit.

[0071] 3.33 Experimental Results: Referring to Figure 2, ELISA detection showed that serum IL-4 and IL-5 levels were significantly elevated in the Model group. All treatment groups reduced these levels, but group B showed the greatest reduction, significantly better than group A (pure product), GS-L group, and GS-H group (P<0.01). RT-qPCR results further indicated that group B also exhibited the strongest inhibitory effect in downregulating the mRNA expression of key asthma signaling pathway molecules MAPK1 and NF-κB p65. All quantitative data are summarized in Tables 1 and 2.

[0072] 4. Results Data Table 1: Comparison of behavioral scores and key inflammatory markers among different groups of mice (x ± s)

[0073] Note: Dosage: Composition A (8 mg / kg), GS-L (120 mg / kg), GS-H (120 mg / kg), Composition B (120 mg / kg).

[0074] Compared with the Model group, *P < 0.05, **P < 0.01; compared with the GS-H group, △P < 0.05, △△P < 0.01; ##P < 0.01 vs Control.

[0075] Table 2: Relative mRNA expression levels of key genes in lung tissue pathways in each group of mice

[0076] Note: Expression levels were standardized with the Control group set to 1; statistical markers are the same as in Table 1.

[0077] 5. Experimental Conclusions

[0078] Although the combination group A (pure product) and the ordinary ginseng total saponin group (GS-L) had certain therapeutic effects, the degree of improvement of various indicators was similar and none of them were outstanding, proving that there is a bottleneck in the efficacy of simply using pure Rg1 / Rb1 or low-purity total saponins.

[0079] The standardized total saponin group (GS-H) showed better efficacy than the previous two groups, proving that standardizing the Rg1+Rb1 content in ginseng total saponins to the range required by this invention (50-70%) is the basis for ensuring its significant efficacy.

[0080] The composition B of this invention (corresponding to the standardized total ginsenosides of Example 1a, with the addition of pure Rg1 and pure Rb1) was significantly superior to all other treatment groups in all tested indicators, including the GS-H group with the best efficacy (P<0.05) and the control group using only standardized total ginsenosides (P<0.01). This result directly and strongly demonstrates that the synergistic effect originates from the combined action of specific known saponins and specific unknown saponin groups, rather than a simple additive effect.

[0081] Experiments have shown that the remarkable therapeutic effect of adding a specific proportion of pure Rg1 and Rb1 to standardized ginsenoside total saponins (GS-H) is not a simple dose-response relationship, but rather stems from a qualitatively transformative synergistic process. The key to this synergistic effect lies in the small amount of unknown saponin components present in GS-H. These unknown saponins, together with the high content of Rg1 and Rb1, constitute an optimized microenvironment, significantly amplifying the inhibitory efficacy against Th2-type inflammation through multi-target action, thus producing an unexpected synergistic effect of "1+1+1 > 3".

[0082] The composition of this invention exhibits comprehensive and significant advantages in inhibiting inflammatory cell infiltration, reducing the level of Th2 inflammatory factors, and inhibiting the key MAPK / NF-κB signaling pathway.

[0083] The various embodiments in this specification are described in a progressive manner. Similar or identical parts between embodiments can be referred to interchangeably. Each embodiment focuses on describing the differences from other embodiments. In particular, the device embodiments are basically similar to the method embodiments, so the description is relatively simple; relevant parts can be referred to the descriptions of the method embodiments.

[0084] The above description is merely a specific embodiment of the present invention, but the scope of protection of the present invention is not limited thereto. Any variations or substitutions that can be easily conceived by those skilled in the art within the technical scope disclosed in the present invention should be included within the scope of protection of the present invention. Therefore, the scope of protection of the present invention should be determined by the scope of the claims.

Claims

1. The application of a ginsenoside composition in the preparation of a drug for treating asthma, wherein, The ginsenoside composition comprises 4 to 8 parts by weight of ginsenoside Rg1 and 1 to 3 parts by weight of ginsenoside Rb1.

2. The application as described in claim 1, characterized in that, The ginsenoside composition also includes 2 to 4 parts by weight of total ginsenosides.

3. The application as described in claim 2, characterized in that, The total weight of ginsenoside Rg1 and ginsenoside Rb1 in the ginsenoside composition accounts for 80% to 90% of the total weight of the composition.

4. The application as described in claim 3, characterized in that, The total weight of ginsenoside Rg1 and ginsenoside Rb1 in the total ginsenosides accounts for 50% to 70% of the total weight of the total ginsenosides.

5. The application as described in claim 4, characterized in that, The total weight of ginsenoside Rg1 and ginsenoside Rb1 in the total ginsenosides accounts for 62% of the total weight of the total ginsenosides.

6. The application as described in claim 2, characterized in that, The method for preparing the total ginsenosides: a) Extraction: Using the dried main root of ginseng (Araliaceae family) as raw material, extract with 6-10 times the amount of 50%-70% ethanol aqueous solution by heating and reflux 2-3 times, each time for 1-2 hours, and combine the extracts; b) Purification: The obtained extract was concentrated until there was no alcohol odor, and then dispersed in water to prepare a loading solution, which was then passed through a D101 macroporous adsorption resin column. c) Elution: First, elute with 3-5 column volumes of deionized water to remove impurities, then elute with 4-6 column volumes of 60%-70% ethanol aqueous solution, and collect the ethanol eluent. d) Post-processing: The ethanol eluent was concentrated to dryness under reduced pressure and then vacuum dried at 60°C to obtain the total ginsenosides.

7. A method for preparing a ginsenoside composition, characterized in that, The method includes: physically mixing 4-8 parts by weight of ginsenoside Rg1, 1-3 parts by weight of ginsenoside Rb1 and 2-4 parts by weight of total ginsenoside powder prepared according to claim 6, and mixing in a V-type mixer at a speed of 20-30 rpm for 30-60 minutes until the mixture is homogeneous.

8. The application as described in any one of claims 1-5, characterized in that, The preparation method of the drug is as follows: the ginsenoside composition is mixed with pharmaceutically acceptable excipients to form tablets, capsules, granules or oral liquid.

9. The application as described in any one of claims 1-5, characterized in that, The asthma mentioned is allergic asthma.

10. A ginsenoside composition, characterized in that, The ginsenoside composition comprises 4-8 parts by weight of ginsenoside Rg1, 1-3 parts by weight of ginsenoside Rb1, and 2-4 parts by weight of total ginsenosides; wherein the total weight of ginsenoside Rg1 and ginsenoside Rb1 accounts for 50%-70% of the total weight of the total ginsenosides.

Images